Agilent Technologies, Inc. $A Holdings Lifted by Meeder Asset Management Inc.

Key Points

• Meeder Asset Management increased its Agilent Technologies stake by 13,407.7% in the second quarter, ending with 27,961 shares valued at approximately $3.7 million. Several other institutional investors also raised their positions, including Deutsche Bank, which added more than 1 million shares.
• Analysts maintain a favorable outlook on Agilent, with a consensus rating of “Moderate Buy” and an average price target of $160.24. Recent targets range from $155 to $165, despite some firms reducing their estimates.
• Agilent exceeded quarterly expectations, reporting $1.49 in adjusted EPS on $1.83 billion in revenue, with revenue up 10% year over year. Management issued fiscal 2026 EPS guidance of $6.00–$6.10, while the stock recently traded at $148.66.

Meeder Asset Management Inc. raised its position in Agilent Technologies, Inc. (NYSE:A - Free Report) by 13,407.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,961 shares of the medical research company's stock after purchasing an additional 27,754 shares during the quarter. Meeder Asset Management Inc.'s holdings in Agilent Technologies were worth $3,714,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in A. Citizens Financial Group Inc. RI raised its holdings in Agilent Technologies by 41.0% during the second quarter. Citizens Financial Group Inc. RI now owns 6,047 shares of the medical research company's stock worth $803,000 after purchasing an additional 1,759 shares in the last quarter. UNIVEST FINANCIAL Corp lifted its holdings in shares of Agilent Technologies by 1.3% in the second quarter. UNIVEST FINANCIAL Corp now owns 7,145 shares of the medical research company's stock valued at $949,000 after buying an additional 93 shares during the period. Quent Capital LLC boosted its stake in Agilent Technologies by 27.4% during the second quarter. Quent Capital LLC now owns 1,746 shares of the medical research company's stock valued at $232,000 after buying an additional 375 shares in the last quarter. Pallas Capital Advisors LLC raised its position in Agilent Technologies by 3.1% in the second quarter. Pallas Capital Advisors LLC now owns 12,937 shares of the medical research company's stock worth $1,718,000 after acquiring an additional 386 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in shares of Agilent Technologies by 17.1% during the 2nd quarter. Deutsche Bank AG now owns 7,008,634 shares of the medical research company's stock valued at $930,957,000 after purchasing an additional 1,024,516 shares in the last quarter.

Analyst Upgrades and Downgrades

A has been the subject of a number of research reports. Sanford C. Bernstein assumed coverage on shares of Agilent Technologies in a report on Friday, June 26th. They set an "outperform" rating and a $155.00 target price for the company. HSBC cut their price objective on Agilent Technologies from $180.00 to $165.00 and set a "buy" rating for the company in a research report on Wednesday, June 3rd. TD Cowen lifted their target price on Agilent Technologies from $147.00 to $155.00 and gave the stock a "buy" rating in a report on Thursday, May 28th. Robert W. Baird upped their target price on Agilent Technologies from $155.00 to $156.00 and gave the company an "outperform" rating in a report on Tuesday, May 26th. Finally, Wells Fargo & Company dropped their price target on Agilent Technologies from $165.00 to $160.00 and set an "overweight" rating on the stock in a research note on Thursday, May 28th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $160.24.

Agilent Technologies Stock Performance

A stock opened at $148.66 on Wednesday. The stock has a market cap of $41.98 billion, a P/E ratio of 29.85, a P/E/G ratio of 2.63 and a beta of 1.25. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.62 and a current ratio of 2.10. The firm has a 50 day simple moving average of $135.97 and a 200 day simple moving average of $125.68. Agilent Technologies, Inc. has a 52 week low of $108.35 and a 52 week high of $160.27.

Agilent Technologies (NYSE:A - Get Free Report) last posted its quarterly earnings results on Wednesday, May 27th. The medical research company reported $1.49 EPS for the quarter, beating the consensus estimate of $1.41 by $0.08. The business had revenue of $1.83 billion for the quarter, compared to analysts' expectations of $1.80 billion. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. Agilent Technologies's revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.31 EPS. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. Research analysts anticipate that Agilent Technologies, Inc. will post 6.03 earnings per share for the current fiscal year.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source